Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study

Hanh-Hung Dao1,2*, Quan-Trung Do3, Junichi Sakamoto1

Abstract

Introduction: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality due to cardiovascular disease, and this occurs early in the disease process. The metabolic syndrome (MetS) may contribute to the excess cardiovascular burden observed in RA; however, little information is available regarding MetS in early RA. We aimed to identify the prevalence of MetS and to determine the potential factors associated with the presence of MetS in Vietnamese women with early RA.

Methods: A total of 105 consecutive women with early RA (disease duration ≤3 years) and 105 age-matched healthy women were checked for MetS according to six MetS definitions (Joint Consensus, International Diabetes Federation, National Cholesterol Education Program 2004 and 2001, European Group for Study of Insulin Resistance, and World Health Organization). Multivariate logistic regression models were constructed to determine independent predictors of MetS in women with RA.

Results: Prevalence of MetS varied from 16.2% to 40.9% according to the definitions used in women with RA, and was higher (P < 0.001) than in healthy controls (from 10.5% to 22.9%). Among individual components of MetS, differences between women with RA and controls were observed for hypertension (P < 0.001), low high density lipoprotein-cholesterol (HDL-C) levels (P < 0.001), and abdominal obesity (P = 0.019). After adjusting for age and physical activity, higher erythrocyte sedimentation rate (ESR) (odds ratios (OR) = 1.516, 95% confidence interval (CI): 1.073 to 3.195, P = 0.042), disease activity score (DAS28) (OR = 1.736, 95% CI: 1.293 to 2.786, P = 0.019), health assessment questionnaire (HAQ) score (OR = 1.583, 95% CI: 1.195 to 2.367, P = 0.035), and less methotrexate use (OR = 0.736, 95% CI: 0.547 to 0.962, P = 0.024) remained significant independent predictors of the presence of MetS in women with RA.

Conclusions: Women with early RA already had higher prevalence of MetS compared with healthy controls. Higher systemic inflammatory marker, disease activity and disability scores, and less methotrexate use were independent predictors associated with the presence of MetS in women with early RA. These findings suggest that physicians should screen for MetS in women with early RA to control its components and therefore reduce their risk of cardiovascular diseases.
estimates are based on information from the general population, however, little information regarding these models is available in RA populations [5,8].

Although traditional cardiovascular risk factors such as hypertension [2,9], central obesity [10,11], dyslipidaemia [12,13], and insulin resistance [14-16] may occur more frequently among patients with RA, this does not fully account for the rates of CVD observed [17], novel risk factors, particularly systemic inflammation, have also been implicated [18].

Metabolic syndrome (MetS), also known as syndrome X and insulin resistance syndrome, is a cluster of classical cardiovascular risk factors including insulin resistance, central obesity, hypertension, high triglycerides (TG) and low HDL levels [19]. MetS has been identified as an independent cardiovascular risk factor, conferring risk beyond the sum of its individual components [20]. MetS increases the risk for atherosclerotic CVD up to three times, and for type 2 diabetes mellitus up to five times [21]. Furthermore, MetS also increases mortality from CVD and all-causes in the general population [22]. At present, six definitions for MetS have been established: the Joint Consensus 2009 of the International Diabetes Federation (IDF) Task Force, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity [23], the IDF 2005 [24], the National Cholesterol Education Program (NCEP) 2004 [21] and 2001 [25], the European Group for Study of Insulin Resistance (EGIR) 1999 [26], and the World Health Organization (WHO) 1998 [27]. These definitions have many similarities; however, they differ in some of the components, as well as in their specified cut-offs and weighting. In the general population, the prevalence of MetS has been shown to vary considerably according to the definition used, with the IDF criteria tending to report the highest and the EGIR criteria the lowest [23]. In patients with RA to date, eight other studies [28-35] and two reviews [36,37] have commented on the prevalence of MetS, reporting prevalence rates ranging from 12.1 to 45.3%, but most of the studies have been conducted in the long-standing disease (9.5 to 24 years). There is evidence that under a given body mass index (BMI), body fat percentage is greater in Asians than Caucasians [47], and greater in RA patients than controls [48]. Therefore, Asian RA patients may be predisposed to more unfavourable cardiometabolic risk; however, there is no available information in the literature regarding MetS in this population.

During the last two decades, the socio-economic condition and lifestyle have profoundly changed in Vietnam; and these changes had strong effects on disease patterns in the population [49]. The prevalence of non-communicable diseases such as obesity, hypertension, and diabetes has been rapidly increasing; and the relationship among urbanization, sedentary lifestyle and these diseases was also demonstrated [49]. The mean BMI of Vietnamese increased from 19 to 23 kg/m²; and the prevalence of MetS recently reached 12% in the general population [50]. However, MetS has not yet been studied among patients with RA in Vietnam. Therefore, the present study was designed to (1) identify the prevalence of MetS according to all definitions currently used, in order to compare between other studies and (2) determine the potential factors associated with the presence of MetS in Vietnamese women with early RA.

Materials and methods

Study design and subjects

This study was designed as a cross-sectional investigation with two comparison groups. The first comprised 105 consecutive Vietnamese women with RA, from 26 to 73 years, who visited our Outpatient Department from October 2007 to March 2009. The second group was made up of 105 age-matched (± 2 years) healthy women who were selected randomly from applicants for an annual health check. They were judged normal on physical examination. All patients fulfilled the American College of Rheumatology (ACR) 1987 classification criteria for RA [51], with disease duration ≤3 years. Written informed consent based on the Helsinki Declaration was obtained from each subject. The study was approved by the Research and Ethical Review Board of the Bach Mai University Hospital, Hanoi, Vietnam.

Assessments

Interviews were performed with a questionnaire identifying risk factors for MetS, such as lifestyle, age, smoking, menopausal status, disease duration and RA medications. A family history of coronary-artery disease was defined as a first-degree relative having had a myocardial infarction or stroke before age 55 in males and 65 in females [31]. Physical activity was defined by the seven-day physical activity recall questionnaire [52]. The assessments include a clinical examination, comprising swollen joint count (28 joints) and tender joint count (28 joints). Patients were also evaluated in terms of
disease activity and disability using the disease activity score (DAS28) (using erythrocyte sedimentation rate (ESR) [53] and the Health Assessment Questionnaire (HAQ) [54], respectively. Pain and general health were measured by a visual analogue scale (VAS).

Height and weight were measured and BMI was calculated as body weight divided by the square of the height (kg/m²). In accordance with WHO standards, for Asian populations, individuals with a BMI <18.5 kg/m² are considered underweight, between 18.5 to 22.9 as normal, 23 to 27.49 as overweight and values greater than 27.5 indicate obesity [55]. Waist circumference (WC) was measured with an inelastic tape, placed directly on the skin, perpendicularly to the long axis of the body while the subject stood balanced on both feet, with both arms hanging freely. The measurement was taken at the end of expiration, at the midway between the costal arch and the iliac crest to the nearest 0.1 cm. BP was measured by a mercury sphygmomanometer in the sitting position after five minutes of rest.

Biological tests were performed from venous blood samples obtained the morning after an overnight fast. Plasma fasting glucose (FG) levels were measured using the glucose oxydase method. HDL-C and low-density lipoprotein cholesterol (LDL-C) levels were measured using corresponding non-precipitating method. Serum creatinine, TG, and total cholesterol (TC) were measured by an auto-analyser (Olympus AU 400, Olympus, Tokyo, Japan). A renal function assessment was performed by estimation of glomerular filtration rate according to the Modification of Diet in Renal Disease (MDRD) equation. For women with RA, rheumatoid factor (RF) and ESR were additionally measured. IgM-RF was assessed by enzyme-linked immunosorbent assay (ELISA), with sero- positivity defined as ≥40 units.

The estimated cardiovascular risk of fatal CVD within 10 years was calculated using the SCORE model [7], according to the EULAR recommendations for cardiovascular risk management in patients with RA and other forms of inflammatory arthritis [5]. A cut-off point of SCORE >10% was used to define the subjects at high risk cardiovascular [5,7].

MetS was assessed according to all existing definitions (Joint Consensus [23], IDF [24], NCEP 2004 [21] and 2001 [25], EGIR [26], and WHO [27]). Details of these criteria are presented in Table 1.

Statistical analyses

Data were presented as mean and 95% confidence interval (CI) for normally distributed continuous variables as well as median and inter-quartile range for skewed continuous variables. Frequency and percentage were used for categorical variables. Comparisons of the values between women with RA and controls were performed using the paired t-test for continuous variables and the chi-square test for categorical variables. Multivariate logistic regression models were constructed and odds ratios (OR) and 95% CI were calculated to investigate the independent of the predictors of individual RA-related characteristics and MetS in women with RA. All statistical analyses were done using the SPSS version 17.0 for Windows (SPSS Inc, Chicago, IL, USA). Statistical significance was defined as the two-tailed P-value < 0.05.

Results

Descriptive characteristics of study population

The median age was 56.3 and 55.7 years in women with RA and healthy controls, respectively. Women with RA had median disease duration of 21 months, and moderate disease activity (mean DAS28 score 4.1). The proportion of patients with low (DAS28 score <3.2), moderate (DAS28 score 3.2 to 5.1) and high (DAS28 score >5.1) disease activity were 36.2%, 52.5%, and 11.3%, respectively. The majority of patients with RA were currently treated with disease-modifying anti-rheumatic drugs (DMARDs) (89.5%), and glucocorticoids (68.6%) with mean daily dose of 8.6 ± 3.7 mg. Because biologic DMARDs have not yet been available in Vietnam, thus none of the patients with RA was treated with those drugs. There were no smokers among the participants.

Demographic and anthropometric characteristics of women with RA and healthy controls are presented in Table 2. No significant differences were seen between the two groups according to the proportion of postmenopausal female and family history of coronary disease. Compared with the healthy controls, women with RA had lower physical activity (P < 0.001). Although means of weight and BMI were similar between the two groups, the proportion of women with RA in the normal weight category was lower (P = 0.006), and in the overweight category was higher (P = 0.047) compared with healthy controls. WC was higher in women with RA compared with healthy controls (P = 0.007). Systolic BP was higher (P = 0.017) in women with RA while diastolic BP was similar between the two groups.

Biological characteristics of study population

Means of total cholesterol and triglycerides levels were not significantly different between the two groups. As expected, HDL-C levels were lower (P = 0.018), and TC/HDL-C ratio and LDL-C were higher (P = 0.03 and 0.046, respectively) in women with RA compared with healthy controls. No significant differences were seen between the two groups according to glycaemia, creatinine, and creatinine clearance (Table 3).
Estimated 10-year cardiovascular risk of fatal CVD using the SCORE model

The SCORE function was higher (P < 0.001) and the proportion of high risk (SCORE >10%) in RA patients was almost doubled (15.3% vs 8.6%, P < 0.001) compared to those in healthy controls (Table 3).

Prevalence of the metabolic syndrome in study population according to definition used

There was great diversity in the reported prevalence rates according to the definition used (Table 4). Prevalence of MetS in women with RA ranged from 16.2% to 40.9%, with EGIR reporting the lowest rate, the IDF reporting the highest rate, and the most updated Joint Consensus 2009 criteria and most commonly used NCEP 2004 reporting a rate of 32.4%. The prevalence rates were higher (P < 0.001) than that in healthy controls (ranging from 10.5% to 22.9%), and almost doubled in the young and middle-aged groups, irrespective of the criteria used. The prevalence increased with age (P < 0.001) in both groups (Table 4). Differences among women with RA and healthy controls were present for hypertension (P < 0.001), low HDL-C levels (P < 0.001), and abdominal obesity (P = 0.019). Among individual components of MetS, the most prevalent were low HDL-C levels, abdominal obesity, and hypertension in women with RA; and abdominal obesity, high TG levels, and hypertension in healthy controls (Tables 2 and 3).

### Table 1: A summary of the definitions of the metabolic syndrome

|                  | JC 2009                      | IDF 2005                  | NCEP 2004                  | NCEP 2001                  | EGIR 1999                  | WHO 1998                  |
|------------------|------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Number of criteria| Three or more of:            | And two or more of:       | Three or more of:          | Three or more of:          | And two or more of:        | And two or more of:        |
| Obesity          | Population and country -    | WC ≥ 94 (men)             | WC ≥ 102 (women)           | WC ≥ 102 (men)             | WC ≥ 94 (men)              | BMI > 30 and/or WHR > 0.9  |
|                  | specific definition         | WC ≥ 80 (women)           | WC ≥ 88 (women)            | WC ≥ 88 (women)            | WC ≥ 80 (women)            | (men) WHR > 0.85 (women)   |
| Hypertension (mmHg) | ≥ 130/85**                   | ≥ 130/85**                 | ≥ 130/85**                 | ≥ 130/85**                 | ≥ 140/90**                 | ≥ 140/90                   |
| HDL-C (mmol/l)   | < 1.0 (men) < 1.3 (women)**  | < 1.0 (men) < 1.3 (women)**| < 1.0 (men) < 1.3 (women)**| < 1.0 (men) < 1.3 (women)**| < 1.0**                    | < 0.9 (men) < 1.0 (women)**|
| TG (mmol/l)      | ≥ 1.7**                      | ≥ 1.7**                    | ≥ 1.7**                    | ≥ 1.7**                    | > 2.0**                    | ≥ 1.7**                    |
| Glucose (mmol/l) | ≥ 5.6**                      | ≥ 5.6**                    | ≥ 5.6**                    | ≥ 6.1**                    | ≥ 6.1, insulin in top 25%  |
| Albumin/creatinine (mg/l) | N/A                          | N/A                       | N/A                       | N/A                       | N/A                       | ≥ 30                       |

Text in italics: prerequisite for diagnosis, in addition to the number of other criteria needed to be met. * cut-off values differ according to ethnic origin, ** or treated for abnormality. BMI: body mass index; DM, diabetes mellitus; EGIR, European Group for Study of Insulin Resistance; HDL-C, high-density lipoprotein-cholesterol; IDF, International Diabetes Federation; IGT, impaired glucose tolerance; IR, insulin resistance; JC, Joint Consensus; N/A, not applicable; NCEP/ATP, National Cholesterol Education Program Adult Treatment Panel; TG, triglycerides; WC, waist circumference; WHO, World Health Organization; WHR, waist hip ratio.

### Table 2: Demographic and anthropometric characteristics of women with RA and healthy controls

| Variables                              | RA patients (n = 105) | Controls (n = 105) | P-value  |
|----------------------------------------|-----------------------|--------------------|----------|
| Age, median (range), years             | 56.3 (26 to 73)       | 55.7 (25 to 72)    | 0.583    |
| Postmenopausal female, n (%)           | 52 (49.5)             | 49 (46.7)          | 0.394    |
| Family history of coronary disease, n (%) | 22 (20.9)            | 23 (21.9)          | 0.138    |
| Regular intentional exercise, n (%)    | 26 (24.8)             | 43 (40.9)          | <0.001   |
| Body weight, kg                        | 54.7 (53.3 to 56.1)   | 53.4 (51.9 to 54.8)| 0.369    |
| Body mass index (BMI), kg/m²           | 23.1 (22.4 to 23.8)   | 22.5 (21.9 to 23.2)| 0.473    |
| Underweight (BMI < 18.5), n (%)        | 12 (11.4)             | 9 (8.6)            | 0.296    |
| Normal weight (BMI: 18.5 to 22.9), n (%) | 41 (39.1)            | 52 (49.5)          | 0.006    |
| Overweight (BMI: 23 to 27.4), n (%)    | 37 (35.2)             | 31 (29.5)          | 0.047    |
| Obese (BMI ≥ 27.5), n (%)              | 15 (14.3)             | 13 (12.4)          | 0.317    |
| Waist circumference, cm                | 85.3 (83.8 to 86.8)   | 78.5 (77.2 to 79.8)| 0.007    |
| Waist circumference ≥ 88, n (%)        | 16 (15.2)             | 9 (8.6)            | 0.005    |
| Waist circumference ≥ 80, n (%)        | 49 (46.7)             | 32 (30.5)          | 0.019    |
| Systolic blood pressure, mmHg          | 128.3 (126.1 to 130.5)| 117.6 (115.5 to 119.7)| 0.017    |
| Diastolic blood pressure, mmHg         | 79.1 (77.9 to 80.3)   | 73.4 (72.3 to 74.5)| 0.343    |
| Blood pressure ≥ 130/85 mmHg, n (%)    | 39 (37.1)             | 27 (25.7)          | <0.001   |

Values are the mean (95% CI) unless otherwise indicated.
The proportion of high risk (SCORE >10%) was lower \((P < 0.05)\) than prevalence of MetS, irrespective of the criteria used in the both women with RA and healthy controls (Tables 3 and 4).

### Associations of the metabolic syndrome in women with RA

Characteristics of women with RA who had and who did not have MetS are presented in Table 5. Results presented were only for the NCEP 2004 criteria, but were very similar when we used other criteria, despite the difference in prevalence.

In univariate analysis, women with RA with the MetS were older \((P = 0.003)\), had less regular intentional exercise \((P < 0.001)\), longer disease duration \((P = 0.046)\), higher RF positivity \((P = 0.049)\), higher ESR \((P = 0.038)\), higher DAS28 score \((P = 0.007)\), higher HAQ score \((P = 0.043)\), higher SCORE function \((P < 0.001)\), higher proportion of SCORE >10% \((P < 0.001)\), higher anti-hypertensive and statin/fibrate use \((P < 0.001)\), and less methotrexate use \((P < 0.001)\), compared with those who did not have the MetS. Sulphasalazine, hydroxychloroquine, glucocorticoids and NSAIDs/COX-II use were not significantly associated with the presence of the MetS. The independence of each of these associations was tested in a multivariate logistic regression model.

After adjusting for age and physical activity, higher ESR \((OR = 1.516, 95\% CI: 1.073 to 3.195, P = 0.042)\), higher DAS28 score \((OR = 1.736, 95\% CI: 1.293 to 2.786, P = 0.019)\), higher HAQ score \((OR = 1.583, 95\% CI: 1.195 to 2.072, P = 0.019)\), higher anti-hypertensive and statin/fibrate use \((P < 0.001)\), and less methotrexate use \((P < 0.001)\), compared with those who did not have the MetS. Sulphasalazine, hydroxychloroquine, glucocorticoids and NSAIDs/COX-II use were not significantly associated with the presence of the MetS. The independence of each of these associations was tested in a multivariate logistic regression model.

### Table 3 Biological characteristics and SCORE of women with RA and healthy controls

| Variables                  | RA patients \((n = 105)\) | Controls \((n = 105)\) | \(P\)-value |
|----------------------------|---------------------------|------------------------|-------------|
| Total cholesterol, mmol/l  | 5.3 (5.2 to 5.4)          | 5.2 (5.1 to 5.3)       | 0.296       |
| Total cholesterol ≥5.2, n (%) | 52 (49.5)                | 50 (47.6)              | 0.413       |
| HDL-cholesterol, mmol/l    | 1.33 (1.29 to 1.37)       | 1.68 (1.62 to 1.74)    | 0.018       |
| HDL-cholesterol ≤1.29, n (%) | 53 (50.5)                | 24 (22.9)              | <0.001      |
| Total cholesterol/HDL to C ratio | 3.98 (3.77 to 4.19)     | 3.09 (2.86 to 3.32)    | 0.037       |
| LDL-cholesterol, mmol/l    | 3.1 (2.9 to 3.2)          | 2.6 (2.5 to 2.7)       | 0.046       |
| LDL-cholesterol ≥2.6, n (%) | 49 (46.7)                | 48 (45.7)              | 0.161       |
| Triglycerides, mmol/l      | 2.07 (2.04 to 2.11)       | 1.96 (1.94 to 1.98)    | 0.134       |
| Triglycerides ≥1.69, n (%) | 33 (31.4)                | 31 (29.5)              | 0.193       |
| Glycemia, mmol/l           | 5.4 (5.3 to 5.5)          | 5.3 (5.2 to 5.4)       | 0.177       |
| Glycemia ≥6.1, n (%)       | 10 (9.5)                 | 9 (8.6)                | 0.219       |
| Glycemia ≥5.6, n (%)       | 17 (16.2)                | 15 (14.3)              | 0.167       |
| Creatinine, mmol/l         | 69.2 (67.9 to 70.4)       | 68.7 (67.5 to 69.9)    | 0.574       |
| Creatinine clearance (ml/min) | 80.8 (78.6 to 83.1)     | 81.6 (79.4 to 83.8)    | 0.358       |
| SCORE function, %, mean (S.D.) | 8.9 (3.6)              | 5.8 (2.7)              | <0.001      |
| SCORE >10%, n (%)          | 16 (15.3)                | 9 (8.6)                | <0.001      |

Values are the mean (95% CI) unless otherwise indicated. HDL, high-density lipoprotein; LDL, low-density lipoprotein. RA, rheumatoid arthritis; SCORE, Systemic Coronary Risk Evaluation.

### Table 4 Prevalence of metabolic syndrome according to different criteria used

| n   | JC 2009 | IDF 2005 | NCEP 2004 | NCEP 2001 | EGIR 1999 | WHO 1998 |
|-----|---------|----------|-----------|-----------|-----------|----------|
| RA  | 105     | 34 (32.4)‡† | 43 (40.9)‡ | 34 (32.4)‡† | 26 (24.7)‡ | 17 (16.2)‡ | 20 (19.0)‡† |
| Controls | 105 | 19 (18.1) | 24 (22.9) | 19 (18.1) | 15 (14.2) | 11 (10.5) | 13 (12.4) |
| 20 to 39 years | RA | 19 | 5 (26.3)† | 7 (36.8)† | 5 (26.3)† | 2 (10.6)† | 1 (5.3)† | 1 (5.3)† |
| Controls | 19 | 2 (10.6) | 3 (15.8) | 2 (10.6) | 1 (5.3) | 0 (0) | 0 (0) |
| RA  | 51     | 16 (31.4)† | 21 (41.2)‡ | 16 (31.4)‡ | 13 (25.5)‡ | 8 (15.7)† | 10 (19.0)† |
| Controls | 51 | 8 (15.7) | 10 (19.6) | 8 (15.7) | 7 (13.7) | 5 (9.8) | 6 (11.8) |
| ≥60 years | RA | 35 | 13 (37.1)† | 17 (48.6)‡ | 13 (37.1)† | 11 (31.4)† | 8 (22.9)‡ | 9 (25.7)† |
| Controls | 35 | 9 (25.7) | 11 (31.4) | 9 (25.7) | 7 (20.0) | 6 (17.1) | 7 (20.0) |

Values are the number (%); EGIR, European Group for Study of Insulin Resistance; IDF, International Diabetes Federation; JC, Joint Consensus; NCEP/ATP, National Cholesterol Education Program Adult Treatment Panel; RA, rheumatoid arthritis; WHO, World Health Organization. †: \(p < 0.001\) for comparison between RA patients and healthy controls; ‡: \(p < 0.001\) for comparison between different age groups in RA patients and healthy controls.
2.367, \( P = 0.035 \), and less methotrexate use (OR = 0.736, 95% CI: 0.547 to 0.962, \( P = 0.024 \)) remained significant independent predictor of the presence of the MetS in women with RA (Table 6).

**Discussion**

This study was carried out in Vietnamese women with early RA and found that: 1. Prevalence of the MetS was significantly higher, almost doubled in the young and middle-aged groups, in women with RA compared with healthy controls, irrespective of the criteria used. 2. In women with RA, higher systemic inflammatory markers, or disease activity and disability scores, and less methotrexate use were independent predictors associated with the presence of the MetS, independently to age and physical activity.

To our knowledge, this is the first study to investigate the prevalence of MetS using all definitions in Asian patients with RA, and the second study in early RA in the literature [31]. Although most experts recognize that obesity-related insulin resistance may be the fundamental cause of MetS, each society has its emphasis in defining the syndrome. The WHO criteria [27] and the EGIR criteria [26] centre on diabetes and insulin resistance, whereas the IDF [24] focuses on central obesity as the essential condition, while the NCEP guidelines [21,25] give equal weight to each component of MetS like Joint Consensus 2009 [23]. Furthermore, cut-off points of individual components of MetS, particularly for WC, are different between the definitions (Table 1). This may explain a great diversity in the prevalence of MetS according to the definitions used, with EGIR reporting the lowest rate, the IDF criteria reporting the highest rate as shown in ours and an earlier study [32]. We used all MetS definitions currently used in order to compare our results to those of previous studies in patients with RA [28-35] and in the Vietnamese population [50]. The prevalence of MetS in women with early RA in our study was significantly higher than that in

| Table 5 Characteristics of women with RA according to the presence or absence of metabolic syndrome |
|---------------------------------------------------------------------------------------------------|
| Variables | Total (n = 105) | With MetS (n = 34) | Without MetS (n = 71) | \( P \)-value |
| Demographics | | | | |
| Age, median (range), years | 52.7 (26 to 71) | 54.6 (26 to 71) | 50.8 (26 to 71) | 0.003 |
| Postmenopausal women, n (%) | 52 (49.5) | 16 (47.1) | 36 (50.7) | 0.271 |
| Regular intentional exercise, n (%) | 26 (24.8) | 5 (14.3) | 21 (29.6) | <0.001 |
| Family history of CHD, n (%) | 22 (20.9) | 7 (20.6) | 15 (21.1) | 0.537 |
| RA disease characteristics | | | | |
| RA duration, median (range), months | 21 (3 to 36) | 26 (3 to 36) | 16 (3 to 36) | 0.046 |
| RF seropositivity, n (%) | 73 (69.5) | 25 (73.5) | 48 (67.6) | 0.049 |
| ESR (mm in first hour), mean (S.D.) | 27.5 (13.9) | 33.6 (11.3) | 21.4 (9.6) | 0.038 |
| DAS28 score, mean (S.D.) | 4.1 (1.3) | 4.7 (1.5) | 3.5 (1.1) | 0.007 |
| HAQ score (range 0 to 3), mean (S.D.) | 0.96 (0.57) | 1.13 (0.58) | 0.79 (0.55) | 0.043 |
| SCORE function, %, mean (S.D.) | 8.9 (3.6) | 9.7 (4.2) | 8.1 (3.1) | <0.001 |
| SCORE >10%, n (%) | 16 (15.3) | 8 (23.6) | 9 (12.6) | <0.001 |
| Current RA medications | | | | |
| Methotrexate, n (%) | 68 (64.8) | 18 (52.9) | 50 (70.4) | <0.001 |
| Sulphasalazine, n (%) | 32 (30.5) | 10 (29.4) | 22 (30.9) | 0.714 |
| Hydroxychloroquine, n (%) | 64 (60.9) | 21 (61.7) | 43 (60.5) | 0.113 |
| NSAIDs/COX-II, n (%) | 29 (27.6) | 10 (29.4) | 19 (26.8) | 0.139 |
| Glucocorticoids use, n (%) | 72 (68.6) | 23 (67.6) | 49 (69.1) | 0.162 |
| Anti-hypertensive, n (%) | 20 (19.1) | 9 (26.5) | 11 (15.5) | <0.001 |
| Statin/fibrate, n (%) | 19 (18.1) | 11 (32.3) | 8 (11.3) | <0.001 |

CHD, coronary heart disease; COX-II, cyclooxygenase II inhibitor; DAS28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; SCORE, Systemic Coronary Risk Evaluation.

| Table 6 Odds ratios for having the metabolic syndrome in women with RA* |
|---------------------------------------------------------------|
| Factors | Odds ratios (95% CI) | \( P \)-value |
| Disease duration | 1.163 (0.971 to 1.924) | 0.372 |
| Rheumatoid factor seropositivity | 1.092 (0.973 to 1.358) | 0.547 |
| ESR | 1.516 (1.073 to 3.195) | 0.042 |
| DAS28 score | 1.736 (1.293 to 2.786) | 0.019 |
| HAQ score | 1.583 (1.195 to 2.367) | 0.035 |
| Methotrexate use | 0.736 (0.547 to 0.962) | 0.024 |

*Analyses are adjusted for age and physical activity, DAS28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis.
healthy controls, irrespective of the criteria used. These findings are in agreement with the results of earlier studies in both early RA [31] and long-standing RA [28-35]. In the literature, prevalence of MetS varied considerably, even using the same criteria; for example, using the NCEP 2001, the prevalence ranged from 17% in Mexican [30], 19% in South African [28], 19.9% in Dutch [34], 38.3% in English [32], to 41.5% in Swedish [33], 42% in American [31], and 44% in Greek [29] patients with RA. Such diversity can be explained by differences in the baseline characteristics and disease characteristics [28-34]. We found that women with RA had higher global estimated 10-year cardiovascular risk of fatal CVD using the SCORE model (based on EULAR guidelines) compared to healthy controls. These findings are in line with the earlier studies [8,56]. The differences between the rate of high risk CVD (SCORE above 10%) and MetS in our study were also reported in the general population using Framingham risk score [57]. The discrepancy may be explained by the fact that many individuals with MetS have borderline elevations in risk factors and thus may actually have either a low or intermediate risk of CVD [58]. It is thus important to determine one’s 10-year cardiovascular risk in order to decide whether or not to start treatment [5,8]. In RA, treatment with statins and/or hypertensive agents should be started when the SCORE is above 10%, provided that the systolic BP is ≥140 mmHg and/or the LDL-C is ≥2.5 mmol/l [5]. It is noted that global risk scoring is heavily dependent on age and, therefore, underestimates risk of CVD in young individuals [57]. As MetS is not likely to replace currently used global risk scoring algorithms, both traditional risk factors and emerging metabolic markers associated with MetS should be incorporated in a future risk scoring system to be developed in order to adapt CVD risk prediction tools to the epidemic of obesity [58]. We found that among individual components of MetS, differences between women with RA and controls were observed for hypertension, low HDL-C levels, and abdominal obesity. These findings are consistent with earlier studies in early RA [31]. The prevalence of hypertension varied from 51.7% to 73% in patients with RA [9]. A consistent pattern of lower HDL-C levels is observed in patients with RA compared with age- and sex-matched controls [12,29,31,45,59] but there is conflict with regard to TC and LDL-C levels. We found TC levels were similar between the two groups while the atherogenic index (TC/HDL-C ratio) and LDL-C levels were higher in women with RA. These findings agree with an earlier study [45], but disagree with others [12,31]. Again, such discrepancy may be explained by differences in the baseline characteristics and disease characteristics.

In this study, although the mean of BMI was similar between the two groups, WC was higher in patients with RA compared with healthy controls. These findings agree with the results of earlier study in early RA [31]. The tendency towards abdominal obesity proves to be a better predictor than BMI of cardiovascular risk in the general population [21,24] and in RA [10,11]. The proportion of overweight, in both groups, was lower but overweight and obesity were higher than those in earlier population-based study in Hanoi [60], suggesting that although underweight remains the main concern, overweight and obesity make up an emerging burden in Vietnam.

The association between ESR and DAS28 score with the presence of the MetS in patients with RA in our study was also previously reported [29]. These findings further support the role of chronic inflammation in insulin resistance development [15]. Controlling systemic inflammation using anti-tumour necrosis factor (TNF) agents has been shown to lead to improvements in insulin resistance in patients with RA [16]. A higher HAQ score is likely to be associated with MetS in RA, because patients with more severe disabling disease are likely to lead a less active lifestyle, resulting in increased obesity and alterations in the lipid profile [61]. In this study, less methotrexate use was associated with the presence of MetS in patients with RA. These findings agree with some earlier studies [30,32], but disagree with others [29,62]. These discrepancies may be explained by differences in the baseline characteristics and disease characteristics. Methotrexate use was associated with a reduction in CVD-related mortality [63] and improvements in lipid and glucose profiles, with lower TG levels, higher HDL-C levels and lower plasma glucose [32]. However, the mechanisms of action of methotrexate are not clearly determined; this may be attributed to an anti-inflammatory effect [30] or a drug-specific effect [32]. Further investigations are needed to establish the effect of methotrexate on MetS.

No significant relationship between the presence of MetS and glucocorticoids use in this study was also previously reported [31,32]. Glucocorticoid use is associated with adverse lipid profiles in the general population, and its long-term use is a risk factor for CVD [64]. However, the relationship between glucocorticoid use and cardiovascular risk in patients with RA is complicated by the fact that these drugs tend to be used more often in patients with severe or intractable disease; therefore, it is difficult to determine whether the disease or the treatment increase the risk [64-66].

Prevalence of MetS in healthy controls was higher than that in an earlier study in Vietnam [50]. Furthermore, we also found that the prevalence of MetS increased with age in both groups as also reported in
the earlier reports [31,32]. With the nation’s increasing life expectancy, there will be a significant future increase in the prevalence of MetS. Therefore, weight and MetS control by association of dietary and physical activity enhancement should be emphasized for the prevention of obesity as well as the obesity-related CVD.

The results of this study must be interpreted within the limitations of the methods used. The major limitation was the small number of patients studied and that they were exclusively women. In practice, there were very few men with RA in our department, so we did not include them in this study; consequently, we are not be able to address the full scale problem of MetS in RA in Vietnamese patients. Previous study in the general population in Vietnam showed that men were more susceptible to Westernization through lifestyle modifications [21,50]. One study of 400 patients with RA reported that the prevalence of MetS was similar in men and women [32]; these findings differ from those observed in the general population [21,23-27], where age-matched men have been reported to have higher rates of MetS. This discrepancy may be a consequence of the ongoing inflammatory burden in the patients with RA, altering some of the components of MetS [32]. Further studies with larger patient cohorts with both men and women are useful. Also, we cannot exclude the possibility of patient selection bias, because our hospital is a tertiary referral centre. Another limitation was study design being cross-sectional, so it was not possible to make any cause-effect inference on the relationship between RA characteristics and MetS. Prospective studies should prove valuable in determining these causal relationships.

Conclusions
Women with early RA already had higher traditional cardiovascular risk and prevalence of MetS compared with healthy controls. A higher systemic inflammatory marker, disease activity and disability scores, and less methotrexate use were independent predictors associated with the presence of MetS in women with early RA. These findings suggest that clinicians should screen for MetS in women with early RA to control its components and, therefore, reduce their risk of cardiovascular diseases.

Abbreviations
ACR: American College of Rheumatology; BMI: body mass index; BP: blood pressure; CI: confidence interval; COX-II: cyclooxygenase II inhibitor; CRP: C-reactive protein; CVD: cardiovascular disease; DAS28: 28-joint disease activity score; DMARDs: disease modifying anti-rheumatic drugs; EGR: European Group for Study of Insulin Resistance; ESR: erythrocyte sedimentation rate; FG: fasting glucose; HAQ: Health Assessment Questionnaire; HDL: high density lipoprotein-cholesterol; IDF: International Diabetes Federation; JC: Joint Consensus; LDL: low density lipoprotein; MetS: metabolic syndrome; MDRD: Modification of Diet in Renal Disease; NCEP/ATP: National Cholesterol Education Program Adult Treatment Panel; NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio; RA: rheumatoid arthritis; RF: rheumatoid factor; SCORE: Systemic Coronary Risk Evaluation; TC: total cholesterol; TG: triglycerides; TNF: tumor necrosis factor; VAS: visual analogue scale; WC: waist circumference; WHO: World Health Organization.
9. Panoulas VF, Metsois C, Pace AV, John H, Trehanne GJ, Banks MJ, Kitas GD: Hypertension in rheumatoid arthritis. *Rheumatology* 2008, 47:1286-1298.

10. Inaba M, Tanaka K, Goto H, Sakai S, Yamada S, Naika H, Imanishi Y, Nishizawa Y: Independent association of increased trunk fat with increased arterial stiffening in postmenopausal women with rheumatoid arthritis. *J Rheumatology* 2007, 34:290-295.

11. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, Tracy R, Szkoła M, Bathon M: Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. *Arthritis Rheum* 2010, 62:3173-3182.

12. Choi HK, Seeger JF: Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. *J Rheumatology* 2005, 32:2311-2316.

13. Steiner G, Urowitz MB: Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. *Semrin Arthritis Rheum* 2009, 58:372-381.

14. Dessein PH, Stanwix AE, Joiffe BI: Cardiorespiratory risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. *Arthritis Res* 2002, 4:R5.

15. Shahin D, Ehrasah B, Mestah A, Housen M: Insulin resistance in early unreinited rheumatoid arthritis patients. *Clin Rheinbohn* 2010, 43:661-665.

16. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Vazquez TR, Miranda-Filloy JA, Llorca J: Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy. Ann *N Y Acad Sci* 2010, 1193:153-159.

17. Gonzalez A, Maradit-Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SI, O’Fallon WM, Gabriel SE: Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? *Ann Rheum Dis* 2008, 67:64-69.

18. Snow MH, Mikuls TR: Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. *Curr Opin Rheumatol* 2005, 17:234-241.

19. Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. *Diabetes* 1988, 37:1595-1607.

20. Reilly WP, Rader DJ: The metabolic syndrome: more than the sum of its parts? *Circulation* 2003, 108:1546-1607.

21. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Huntinghde BK, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004, 110:227-239.

22. Ford ES: Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. *Diabetes Care* 2005, 28:1769-1778.

23. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention, National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009, 120:1640-1645.

24. Alberti KG, Zimmet PZ, Shaw J: The metabolic syndrome: a new worldwide definition. *Lancet* 2005, 366:1059-1062.

25. NCEP Expert Panel: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001, 285:2486-2497.

26. Bakau B, Charles MA: Comment on the provisional report from the WHO consultation. *Diabet Med* 1999, 16:442-443.

27. Alberti KGM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. *Diabet Med* 1998, 15:539-553.

28. Dessen PH, Tobias M, Veller MG: Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. *J Rheumatology* 2006, 33:2425-2432.

29. Kavanounias SA, Sidiroopoulos PI, Papadakis IA, Spanakos EK, Bertias GK, Kritikos HD, Gafanakis ES, Boumpas DT: Metabolic syndrome is common among middle-to-old aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled study. *Ann Rheum Dis* 2007, 66:28-33.

30. Zonana-Nacach A, Santana-Sahuagun E, Jimenez-Balderas FJ, Camargo-Coronel A: Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. *J Clin Rheumatology* 2008, 14:71-77.

31. Chung CP, Osei A, Solus JF, Avilas I, Gbessiatdak T, Shintani A, Ragge P, Sokka T, Pincus T, Stein CM: Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. *Atherosclerosis* 2008, 196:756-763.

32. Toom TE, Panoulas VF, John H, Douglas KMI, Kitas GD: Methotrexate therapy associates with a reduced prevalence of metabolic syndrome in rheumatoid arthritis patients over the age of 60: more than just an anti-inflammatory effect? A cross-sectional study. *Arthritis Rheum* 2009, 11:R10.

33. Alcan EA, Hakansson NS, Frostegard J, Cedermolin TH, Hafstrom I: Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. *Arthritis Rheum* 2009, 61:R57.

34. Rateman HG, van Eijk J, Voskuyl AE, Peter ML, Dijkmans BA, van Halm VP, Simels S, Lems WF, Nurmohamed MT: The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study. *Ann Rheum Dis* 2010, 69:39-42.

35. Cochrane DM, Mysoreddi C, Matteson EL, Roger VL, Therneau TM, Fitz-Gibbon P, Rodeheffer RJ, Gabriel SE: Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without cardiovascular disease. *J Rheumatology* 2010.

36. Sidiroopoulos PI, Kavanounias SA, Boumpas DT: Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. *Arthritis Rheum* 2008, 60:2020.

37. Perera RMB, Fiere de Carvalho J, Bonta E: Metabolic syndrome in rheumatological diseases. *Autoimmun Rev* 2009, 8:415-419.

38. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmonds PM: Mortality in early inflammatory polyarthropathy: cardiovascular mortality is increased in seropositive patients. *Ann Rheum Dis* 2002, 61:2010-2019.

39. Young A, Kodun G, Batley M, Kulinskaya E, Gough A, Norton S, Dwyer J. Early Rheumatoid Arthritis Study (ERAS) group: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. *Rheumatology* 2007, 46:350-357.

40. Kumedya Y, Inaba M, Goto H, Nagata M, Henni Y, Furumitsu Y, Ishimura E, Itani K, Yutani Y, Miki T, Shibiki T, Nishizawa Y: Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. *Ann Rheum Dis* 2002, 61:1489-1497.

41. Hannawi S, Haluska B, Manwick TH, Thomas R: Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. *Arthritis Res Ther* 2007, 9:R116.

42. Georgiadis AN, Voulgari PV, Papavassiliou GI, Almanos Y, Elofsson A, Tsilepis AD, Drosos AA: Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. *Rheum Dis Clin North America* 2008, 34:33-42.

43. Sødergren A, Karp K, Boman K, Eriksson C, Lundström E, Smedby T, Voskuyl AE, Huizinga TW, van de Stadt RJ, Dijkmans BA, van der Linden S: Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. *Ann Rheum Dis* 2003, 62:842-846.

44. Wulan SN, Westerterp KR, Pasqua G: Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. *Maturitas* 2010, 65:315-319.

45. Stavropoulou-Kalinoglou A, Metsois G, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, Veldhuizen van Zanten JCS, Labib M, Kitas G: Redefining overweight and obesity in rheumatoid arthritis patients. *Ann Rheum Dis* 2008, 67:70-73.
49. Khan NC, Khoi HH. Double burden of malnutrition: the Vietnamese perspective. Asia Pac J Clin Nutr 2008, 17(Suppl 1):116-118.
50. Son le NT, Kunii D, Hung NTX, Sakai T, Yamamoto S. The metabolic syndrome: prevalence and risk factors in the urban population of Ho Chi Minh City. Diabetes Res Clin Pract 2005, 67:243-250.
51. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
52. Blair SN, Haskell WL, Ho P, Paffenbarger RS Jr, Vranizan KM, Farquhar JW, Wood PJ. Assessment of habitual physical activity by seven-day recall in a community survey and controlled experiments. Am J Epidemiol 1985, 122:794-804.
53. Prevoo ML, van't Hof MA, Kupper HH, van Leeuwen MA, van de Putte LB, van Riel L. Modified disease activity scores that includes twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
54. Wolfe F, Klauser M, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire function disability index in patients with rheumatoid arthritis. J Rheumatol 1988, 15:1460-1488.
55. WHO Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163.
56. Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008, 58:2268-2274.
57. Hoang KC, Ghandehari H, Lopez VA, Barboza MG, Wong ND. Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S. Diabetes Care 2008, 31:1405-1409.
58. Arsenault BJ, Pibarot P, Després JP. The quest for the optimal assessment of global cardiovascular risk: are traditional risk factors and metabolic syndrome partners in crime? Cardiology 2009, 113:35-49.
59. Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Song CH. Lee J. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999, 26:1701-1704.
60. Wall HL, Peeters A, Son PT, Quang NN, Hoai NT, Loi DD, Viet NL, Khai PG, Reid CM. Prevalence of underweight, overweight and obesity in urban Hanoi, Vietnam. Asia Pac J Clin Nutr 2009, 18:234-239.
61. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, Kitas GD. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009, 16:188-194.
62. Raterman HG, Voskuyl AE, Dijkmans BA, Nurmohamed MT. Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome. Arthritis Res Ther 2009, 11:413.
63. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
64. Bijlsma JWJ, van der Goes MC, Hoes JN, Jacobs JWG, Buttgereit F, Kirwan J. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann N Y Acad Sci 2010, 1193:129-126.
65. Davis JM, Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE. Glucocorticoids and cardiovascular events in rheumatoid arthritis. A population-based cohort study. Arthritis Rheum 2007, 56:820-830.
66. Toms TE, Panoulas VF, Douglas KMJ, Griffiths HR, Kitas GD. Lack of association between glucocorticoid use and presence of the metabolic syndrome with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008, 10:R145.